Image source: Shutterstock

Highlights

  • Cash balance of EUR 144.2M as of December 31, 2024, with runway extending into Q4 2025
  • Full enrollment in Phase 3 ABTECT trial for ulcerative colitis expected in Q2 2025
  • Top-line results from 8-week induction trials anticipated in Q3 2025

Abivax SA (Nasdaq:ABVX), a clinical-stage biotechnology company, has announced its financial results for the year ending December 31, 2024. The results were approved by the Company's Board of Directors on March 20, 2025, and will be filed with the French and U.S. securities authorities on March 24, 2025.

As of December 31, 2024, Abivax reported a cash balance of EUR 144.2 million, providing a good financial foundation to continue advancing its clinical development pipeline. This cash position ensures a runway extending into Q4 2025, allowing the company to focus on its Phase 3 ABTECT clinical trial for obefazimod, which is being evaluated for the treatment of moderately to severely active ulcerative colitis (UC). Full enrollment in this pivotal trial is expected by Q2 2025.

The company’s CEO, Marc de Garidel, emphasized the importance of 2025 for Abivax, highlighting key milestones, including the full enrollment of the ABTECT trial and the anticipated top-line results from the 8-week induction trials in Q3 2025. This data will be a critical step in the development of obefazimod as a potential treatment for UC.

Abivax also noted that its operational expenditures increased during 2024, driven by ongoing investments in its clinical programs, particularly the ABTECT trial, and the necessary scale-up of manufacturing processes to support future potential commercialization.

Looking ahead, Abivax’s financial management remains disciplined as it progresses through key milestones in 2025, with the completion of the Phase 3 ABTECT trial’s induction phase expected by Q2 2025 and top-line results slated for Q3 2025. The company is committed to further advancing its mission of developing innovative therapies for chronic inflammatory diseases.